Ticagrelor versus Clopidogrel in <i>CYP2C19</i> Loss-of-Function Carriers with Stroke or TIA.

Y, Wang; X, Meng; A, Wang; X, Xie; Y, Pan; SC, Johnston; H, Li; PM, Bath; Q, Dong; A, Xu; J, Jing; J, Lin; S, Niu; Y, Wang; X, Zhao; Z, Li; Y, Jiang; W, Li; L, Liu; J, Xu; L, Chang; L, Wang; X, Zhuang; J, Zhao; Y, Feng; H, Man; G, Li; B, Wang

doi:10.1056/nejmoa2111749

Public

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.

Shared by NobleBlocks on Oct 28, 2021 • 12:00 AM UTC

Authors:

Wang Y

Meng X

Wang A

Abstract

Background Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.Methods We conducted a randomized, double-blind, placebo-controlled trial at 202 centers in China involving patients with a minor ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!